James Lymp
About James Lymp
James Lymp is the Associate Director of Biostatistics at Bristol Myers Squibb with extensive experience in biostatistics and a background in academia and industry.
Current Title and Role
James Lymp currently holds the position of Associate Director, Biostatistics at Bristol Myers Squibb. In this role, he is responsible for leading statistical analyses and contributing to the development and evaluation of clinical trials. His work focuses on leveraging statistical methods to support the regulatory approval and marketing of new treatments.
Previous Positions in Biostatistics
James Lymp has held various influential positions throughout his career. He worked at Celgene as Associate Director, Statistics in 2019 for 10 months. Prior to that, he was Principal Statistician at Juno Therapeutics, Inc. from 2018 to 2019, and Lead Biostatistician at GRAIL, Inc. from 2017 to 2018. During his career, he has also been an Associate Director of Biostatistics at Ultragenyx Pharmaceutical Inc. from 2015 to 2017, a Statistical Scientist at Genentech from 2011 to 2015, and a Senior Biostatistician at Seattle Children's from 2006 to 2011.
Academic Background and Education
James Lymp completed his PhD and MS in Biostatistics at the University of Washington, finishing his doctoral studies in 1997 and his master's degree in 1994. He obtained his Bachelor of Science degree in Mathematics from Oregon State University. His strong academic background laid the foundation for his career in biostatistics and his contributions to the field.
Contributions to Cancer Research
At GRAIL, Inc., James Lymp developed diagnostic methods for cancer detection. His work contributed to the advancement of non-invasive diagnostics that aim to identify cancer at early, more treatable stages. This role underscored his commitment to improving healthcare outcomes through innovative statistical techniques.
Research Interests and Specializations
James Lymp's research interests include Bayesian methods for decision making, the development of clinical outcome measures, and diagnostic tests. His expertise extends to statistical methodologies that enhance the design and analysis of clinical trials, benefiting the medical community and patients alike. He has engaged in extensive academic research and consulting, notably at institutions such as Mayo Clinic and the University of Washington.